Brind.

Abeona Therapeutics received FDA review of its BLA resubmission for pz-cel on July 1, 2025, and was listed under Nasdaq Rule 5635(c)(4).

1 report, 0 independent Updated Jul 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Abeona Therapeutics FDA

Keep exploring

The entities involved

Abeona Therapeutics
biopharmaceutical company

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

Coverage

Newest first; wire copies grouped

Jul 1Unknown outlet